·¬ΗΡΙηΗψapp

Meeting Coverage

SABCS

San Antonio Breast Cancer Symposium

Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer

Triplet therapy may surpass benefits of current "pretty active doublet" therapy, expert says

SABCS over a photo of the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Latest SABCS Meeting Coverage

Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancer

Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant

December 10, 2023
Less-Frequent Surveillance Mammo Feasible in Older Breast Cancer Survivors

No difference for survival outcomes for annual versus around every 2 years

December 9, 2023
Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer

However, the surgery did reduce risk of contralateral breast cancer

December 9, 2023
Is Omitting Radiation Therapy in Low-Risk Breast Cancer a Good IDEA?

Local recurrence rate of 1% at 5 years in women ages 50-69 with genomically low-risk disease

December 8, 2023
Study Supports ADC as a New Option for Endocrine-Resistant Metastatic Breast Cancer

Datopotamab deruxtecan was safe and boosted quality of life

December 8, 2023
Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC

But better safety profile versus continued pembrolizumab plus chemotherapy

December 8, 2023
Study 'Underscores' Value of Early Fertility Counseling for Breast Cancer Patients

Younger age, embryo/oocyte cryopreservation at diagnosis tied to an increased chance of pregnancy

December 8, 2023
Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer

Promising early results with pembrolizumab, nivolumab but event-free survival data still pending

December 7, 2023
No Benefit to Adjuvant-Only Immunotherapy in Early TNBC

Neoadjuvant administration of immunotherapy remains the preferred approach

December 7, 2023
De-Escalating Breast Cancer Treatment Feasible After Response to Neoadjuvant Chemo

Study showed no increase in disease progression when omitting regional nodal irradiation

December 7, 2023
Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer

Adding agent to T-DM1 resulted in 2-month progression-free survival improvement

December 6, 2023
High Rates of pCR With Novel Neoadjuvant Combination for Breast Cancer

Enthusiasm tempered by immune-related adverse events, diabetes with PD-1/LAG-3 combination

December 11, 2022
Less Is More Wins Again: Avoiding Node Dissection in Early Breast Cancer

First comparison of targeted sentinel node assessment shows no difference in recurrence rates

December 9, 2022
Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer

In phase III trial, capivasertib benefited patients with or without AKT pathway alterations

December 9, 2022

Videos

SABCS Future Focus
December 2023